Publication in The New England Journal of Medicine of interim results from phase 1 study of the mRNA vaccine against COVID-19 (mRNA-1273).- Moderna Inc.
Moderna, Inc. announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of… read more.